Pomalidomide

For research use only. Not for use in humans.

目录号:S1567 别名: CC-4047

Pomalidomide Chemical Structure

Molecular Weight(MW): 273.24

Pomalidomide抑制LPS诱导的TNF-α释放,在PBMCs中IC50为13 nM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 748.13 现货
RMB 576.14 现货
RMB 991.28 现货
RMB 3029.87 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Pomalidomide发表文献39篇:

产品安全说明书

TNF-alpha抑制剂选择性比较

生物活性

产品描述 Pomalidomide抑制LPS诱导的TNF-α释放,在PBMCs中IC50为13 nM。
特性 Pomalidomide是Thalidomide 衍生物,效果比Thalidomide强10,000倍。
靶点
TNF-α [1]
(PBMCs)
13 nM
体外研究

Pomalidomide 抑制脂多糖(LPS)刺激的TNF-alpha释放,作用于人类 PBMC 和人类全部血液时,IC50分别为13 nM 和25 nM。[1] Pomalidomide抑制 IL-2刺激的T 调节细胞,IC50为~1 μM。[2]6.4 nM-10 μM Pomalidomide 处理人类外周血T细胞 ,提高 IL-2 产量,作用于CD4+子集比作用于CD8+子集有效。 Pomalidomide 比CC-5013显著促进IL-2, IL-5,和 IL-10, 比CC-5013稍微促进 IFN-γ。Pomalidomide 作用于Jurkat细胞,增强 SEE和 Raji细胞诱导的 AP-1 转录活性,1 μM时最高增强4倍,这种作用存在剂量依赖性。[3] 用不同浓度Pomalidomide(2.5-40 μg/mL) 处理Raji细胞48小时,导致细胞增殖和DNA合成明显降低,与对照组相比降低~40% 。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLP-8 M4K5UGN6fG:2b4jpZ4l1gSCDc4PhfS=> MXSxNEDPxE1? NISwWXUzPCCq NXjxXVNTeG:2ZX70cJkh[XWpbXXueJMh\Gm{ZXP0JIFv\CCrbnTpdoVkfCCPTTDj[YxtKGurbHzpcoch[nliU1HS Mlf2NlY{Ozh{N{O=
J-CD38 M3jIeGN6fG:2b4jpZ4l1gSCDc4PhfS=> NFvrNmEyOCEQvF2= NVzC[YhNOjRiaB?= MlHEdI91\W62bImgZZVodWWwdIOg[Ilz\WO2IHHu[EBqdmSrcnXjeEBOVSClZXzsJItqdGyrbnegZpkhW0GU M{PKRVI3OzN6Mkez
R-CD38 Mon3R5l1d3SxeHnjbZR6KEG|c3H5 MV[xNEDPxE1? MnPuNlQhcA>? MkL3dI91\W62bImgZZVodWWwdIOg[Ilz\WO2IHHu[EBqdmSrcnXjeEBOVSClZXzsJItqdGyrbnegZpkhW0GU MXGyOlM{QDJ5Mx?=
BC-3 NYr2WGp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\pNG4{QS1zMkWwJI5O NXTwPVhMPSCm M4\nPGROW00EoB?= M2DjZWlEPTB;MUC3JI5ONCCrbnjpZol1eyClZXzsJGlEPTB;MUC3JI5ONCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NYCxWIJiOjZzMUm5N|k>
BCBL-1 M{Wzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf4[5dXOzlvMUK1NEBvVQ>? NHnwT2w2KGR? NVLaN5oyTE2VT9Mg M1TNSWlEPTB;N{Sgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= M13OcFI3OTF7OUO5
JSC-1 M3HlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPyZpA{QS1zMkWwJI5O MXK1JIQ> NXrIS|d2TE2VT9Mg MW\JR|UxRTN2IH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MoLmNlYyOTl7M{m=
VG-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG0N|kuOTJ3MDDuUS=> Mn\BOUBl NVXwV3R[TE2VT9Mg NGPh[YlKSzVyPUGwNUBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> NF7FPIwzPjFzOUmzPS=>
UMPEL-1 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlmzN|kuOTJ3MDDuUS=> MlmwOUBl MkjUSG1UV8Li MYrJR|UxRTN{IH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MUOyOlEyQTl|OR?=
UMPEL-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7CdnBMOzlvMUK1NEBvVQ>? MmnsOUBl NWXqN|JDTE2VT9Mg Ml\uTWM2OD1zMUGgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= M{nWTlI3OTF7OUO5
BC-1 NInXZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPPN|kuOTJ3MDDuUS=> NVnD[4Y1PSCm MWfEUXNQyqB? NYD2[FdWUUN3ME23OFQhdk1uIHnubIljcXS|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NWDYRllOOjZzMUm5N|k>
BCP-1 MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSzPU0yOjVyIH7N M{fWdVUh\A>? MXrEUXNQyqB? M4XQXmlEPTB;M{m2JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 NVzCRZg4OjZzMUm5N|k>
APK-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvuN|kuOTJ3MDDuUS=> NFLrPHU2KGR? M4HyV2ROW00EoB?= M{jlOmlEPTB;MkK2JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 M{LvflI3OTF7OUO5
RPMI8226  M17PV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm2PGQxNjBzLUWwJO69VQ>? NYfCcGdKPDhiaB?= MlPTSG1UV8Li NYPCPXJqUUN3ME24JO69VQ>? NHfne2gzPjB7N{i3Ni=>
OPM2  MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHwN44xNjBzLUWwJO69VQ>? NVXjZ2JrPDhiaB?= NFXoVVBFVVORwrC= MnX1TWM2OD1zMDFOwG0> M2jjTVI3ODl5OEey
RPMI8226  NFfJZo9HfW6ldHnvckBCe3OjeR?= M{G4flExKM7:TR?= MXe0PEBp MWLEUXNQyqB? MWfzeJJmdme2aHXud{BkgXSxcHzhd41q[y2wdXPs[YFzKHOqdYT0cIlv\yCxZjDtWG9TKGGwZDDwMY1VV1JicILveIVqdg>? NXTIOIFGOjZyOUe4O|I>
OPM2  MV;GeY5kfGmxbjDBd5NigQ>? NYnZUnlkOTBizszN MXu0PEBp M4nuO2ROW00EoB?= MmrLd5Rz\W6pdHjlcpMh[3m2b4DsZZNucWNvboXjcIVieiC|aIX0eIxqdmdib3[gcXRQWiCjbnSgdE1uXE:UIIDyc5RmcW5? MWCyOlA6Pzh5Mh?=
RPMI8226 MYTGeY5kfGmxbjDBd5NigQ>? M3jO[FAvOS1zMDFOwG0> MnPLOEBp M4GxSWROW00EoB?= M3uwdYlv[3KnYYPld{BXTUeIIH3SUmEh\XiycnXzd4lwdg>? NGnZTo4zPTB3M{m5NC=>
SH-SY5Y  NHLXOohCeG:ydH;zbZMhSXO|YYm= MYGyOeKh|rypL33M M4H1R|HDqGh? MXTjZZV{\XNic4TheIl{fGmlYXzsfUB{cWewaX\pZ4FvfCC{ZXT1Z5Rqd25iaX6gZo91cCCFUF[tJIFv\CCFUF[rR20ucW6mdXPl[EBieG:ydH;zbZPDqA>? NIX4[IIzPDl5NUK3Oi=>
JJN3 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC1SI1YOC5zLUGwNEDPxE1? MWq3NkBp NF;Mc3lFVVOR MXnpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> M4XqO|I{OTd6M{e4
XG-1 NUG1cFFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTW[3pROC5zLUGwNEDPxE1? MkTEO|IhcA>? NYHqXWF5TE2VTx?= MoDHbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NX71WWJ4OjNzN{izO|g>
CD138+  NHrweHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKwMlEuOTByIN88US=> MVi3NkBp MU\EUXNQ NH3kUXJqdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mni3NlMyPzh|N{i=
XG-1 MWjGeY5kfGmxbjDBd5NigQ>? NVTZRY5POi9zMECg{txO Mnr6NlQhcA>? Ml7nSG1UVw>? M{\teolvcGmkaYTzJGNEVDNxTVnQMVHPuSCvUl7BJIV5eHKnc4Ppc44> NEjBTnczOzF5OEO3PC=>
U266 NXrPb5Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL2R2UxNjBzLUGwJO69VQ>? MlfJOFjjiImq MmfJSG1UVw>? NF\SSItqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MkDnNlI2PTJyMEi=
CRBN60 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zLNlAvODFvMUCg{txO MlTROFjjiImq MnrjSG1UVw>? MofvbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NEfvTZgzOjV3MkCwPC=>
CRNB75 NWPUbJoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr2NE4xOS1zMDFOwG0> M1XlZ|Q56oDLaB?= M3XMV2ROW09? NFSwWlBqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MYqyNlU2OjByOB?=
MM.1S MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPLNE4xOS1zMDFOwG0> NVSwSVk{PDkkgJno M2D2SWROW09? M4q4c5Nq\26rZnnjZY51dHliaX7obYJqfHNicILvcIln\XKjdHnvckBifCClb37j[Y51emG2aX;ud{BieyCub4egZZMhOC5yMd88US=> NHXDOFQzOTN6OUOyOy=>
OPM2 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13ndFAvODFvMUCg{txO MWO0PQKBkWh? MV;EUXNQ NH;v[5F{cWewaX\pZ4FvfGy7IHnubIljcXS|IIDyc4xq\mW{YYTpc44h[XRiY3;uZ4VvfHKjdHnvcpMh[XNibH;3JIF{KDBwMEJOwG0> NFvNO5EzOTN6OUOyOy=>
MM.1S NGSyZZBHfW6ldHnvckBCe3OjeR?= M4rhVFExKM7:TR?= MnTCO|IhcA>? NUTmbmRvTE2VTx?= Moqyd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJJBzd3SnaX6gcIV3\Wxib3[gR{9GSlEQsjDpd49nd3Kvc9Mg NGfISXozOTN6OUOyOy=>
H929 M1[zc2Z2dmO2aX;uJGF{e2G7 NHXYWGsyOCEQvF2= MWq3NkBp M2fxZmROW09? MVvzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgdJJwfGWrbjDs[ZZmdCCxZjDDM2VDWM7{IHnzc4Zwem2|wrC= MX:yNVM5QTN{Nx?=
OPM2 MVPGeY5kfGmxbjDBd5NigQ>? MWexNEDPxE1? NFXRSmQ4OiCq NGe4UHRFVVOR M{\JRZNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> NVW3[mdCOjF|OEmzNlc>
CT26 MoL2SpVv[3Srb36gRZN{[Xl? MlHuNU8yOCEQvF2= MkXGNlQhcA>? MUny[YR2[2W|IITo[UBvfW2kZYLzJI9nKGyrdnWgZ49td26rZYRCpC=> MYWxPVY{QDl5Nx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
CEBPβ; 

PubMed: 21389327     


MM.1S, H929, OPM2, or primary myeloma cells were cultured with DMSO, pomalidomide, or lenalidomide at the indicated concentrations for 3 days. Representative results from 3 independent experiments are shown. Cells were then lysed, and cell lysates were an䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ

IKZF1 / IKZF3 / UBE2G1 / CRBN ; 

PubMed: 30234487     


Immunoblot analysis of SKMM2 cells transduced with lentiviral vectors encoding GFP, UBE2G1 and UBE2G1-C90S. Cells were treated with DMSO vehicle control, LEN or POM at the indicated concentrations for 16 hr.

21389327 30234487
Immunofluorescence
IKZF1; 

PubMed: 29496670     


CD34+ cells were treated with DMSO (0.01%), LEN, or POM (1 μM) for 6 hours. The cells were then fixed and stained for IKZF1 (red color), and nuclear counterstaining was performed with DAPI (blue color). The localization of IKZF1 was observed using a Leica䲧疝Ỵ疞㧀疜膉痘 

29496670
体内研究 Pomalidomide 作用于SCID小鼠,增强 Rituximab作用于B细胞淋巴瘤的抗癌效果。Pomalidomide和Rituximab联用使鼠平均寿命为74天,与 CC5013/Rituximab 处理的鼠平均寿命为58天。NK细胞耗尽则Pomalidomide和Rituximab协同作用完全被废除, 说明NK细胞增多是Pomalidomide增强 Rituximab抗癌的一个机制。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

抑制TNF-α合成实验 :

在内毒素(LPS)刺激的PBMC中测定TNF-α抑制活性。Pomalidomide 加到PBMCs中1小时,然后加入LPS (1 μg/mL),再处理18-20小时。收集悬浮液,通过ELISA测定悬浮液中的TNF-α浓度。通过回归曲线分析计算IC50值。人类全部血液TNF抑制实验和PBMC实验差不多,除了肝素化的新鲜血液直接加到微量滴定法板上。
细胞实验:[4]
- 合并
  • Cell lines: Raji,SU-DHL-4和SU-DHL-10 细胞系
  • Concentrations: 溶于DMSO, 终浓度为2.5-40 μg/mL
  • Incubation Time: 24或48小时
  • Method: 为了测定细胞凋亡,用Pomalidomide(5 μg/mL)处理淋巴瘤细胞系24小时或48小时。用FITC标记的膜联蛋白V和碘化丙啶进行细胞染色。使用荧光激活细胞分选仪/FACStar 和流式细胞仪,通过多色流式细胞仪分析细胞凋亡。如果膜联蛋白V阳性及碘化丙啶阴性/阳性,则判断为细胞凋亡(分布为凋亡早期和晚期)。为了测定细胞增殖,用Pomalidomide(2.5, 5, 10, 20,和40 μg/mL)处理淋巴瘤细胞系24小时或48小时。在96孔板上,每孔加入1 μCi[3H]-胸甘,细胞再温育18小时。收集细胞,加到96孔玻璃过滤器中,然后使用自动闪烁计数器测定摄取的[3H]-胸甘。
    (Only for Reference)
动物实验:[4]
- 合并
  • Animal Models: 携带扩散性淋巴瘤的SCID小鼠
  • Formulation: 溶于DMSO,形成10 mg/mL 溶液,用0.9%无菌盐水稀释,终浓度为1 mg/mL
  • Dosages: 0.5 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 54 mg/mL (197.62 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 273.24
化学式

C13H11N3O4

CAS号 19171-19-8
储存条件 粉状
溶于溶剂
别名 CC-4047

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03798314 Recruiting Biological: Nivolumab|Drug: Pomalidomide Recurrent Nervous System Lymphoma|Recurrent Primary Vitreoretinal DLBCL|Refractory Nervous System Lymphoma|Refractory Primary Vitreoretinal DLBCL Mayo Clinic|National Cancer Institute (NCI) January 30 2019 Phase 1
NCT03567616 Suspended Drug: Venetoclax|Drug: Pomalidomide|Drug: Dexamethasone Multiple Myeloma AbbVie|Celgene October 18 2018 Phase 2
NCT03683277 Not yet recruiting Drug: Ixazomib/Pomalidomide/Dexamethasone Multiple Myeloma|Relapsed and Refractory Multiple Myeloma|Genetic Condition Intergroupe Francophone du Myelome|AXONAL|Nantes University Hospital|University Hospital Grenoble|EURAXI October 1 2018 Phase 2
NCT03113942 Active not recruiting Drug: Pomalidomide 2 MG Oral Capsule [Pomalyst] High Grade Squamous Intra-epithelial Lesion (HSIL) Kirby Institute June 14 2017 Phase 2
NCT03015922 Recruiting Drug: Lenalidomide or Pomalidomide|Biological: REOLYSIN Multiple Myeloma University of Leeds|Myeloma UK|Oncolytics Biotech|Celgene Corporation June 5 2017 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is S1567 in the 1% DMSO+30% polyethylene glycol+1% Tween 80 suitable for oral administration?

  • 回答:

    S1567 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension. This formulation is for oral gavege.

  • 问题 2:

    I would like to know if the pomalidomide is racemic or optically active?

  • 回答:

    Our S1567 Pomalidomide is racemic.

TNF-alpha Signaling Pathway Map

TNF-alpha Inhibitors with Unique Features

相关TNF-alpha产品

Tags: 购买Pomalidomide | Pomalidomide供应商 | 采购Pomalidomide | Pomalidomide价格 | Pomalidomide生产 | 订购Pomalidomide | Pomalidomide代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID